A 2021 approval opened a weight-management use for semaglutide

The signal

FDA's approval letter for NDA 215256, a health-science-sector drug application, approved Wegovy (semaglutide) injection “as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management” in adults with an initial body mass index of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related condition such as hypertension or type 2 diabetes. The letter states the approval is “effective on the date of this letter.” FDA's own Drugs@FDA database records the original approval action date as 4 June 2021, under priority review; the letter document itself carries FDA's file date of 7 June 2021, a short and routine gap between an approval action and the paperwork recording it.

The evidence

The application had been submitted, per the letter, on 4 December 2020, so the review ran roughly six months. Beyond the original approval, FDA's Drugs@FDA record shows the product has kept accumulating supplements rather than settling into a fixed label: an efficacy-related “new indication” supplement in March 2024, further new-indication supplements in August and November 2025, and a new-dosing-regimen supplement in March 2026, alongside repeated labeling updates. That pattern, drawn directly from FDA's own record, documents sustained regulatory and clinical activity around the product over more than four years, though it measures filings, not sales or patient volume.

Timeframe and confidence

Confidence in the original approval date and the indication language is high, since both come directly from FDA's approval letter and its own database. Confidence in what the pattern of supplements implies about market demand is lower: this piece did not open a company financial filing reporting Wegovy's sales, so no revenue figure is stated here, and the supplement count should not be read as a proxy for units sold.

What would change the reading

A Novo Nordisk financial filing disclosing Wegovy segment revenue, opened and cited directly, would let the demand side of this story be quantified rather than inferred from regulatory filing activity alone. A future FDA action withdrawing or narrowing the indication would be the clearest signal that the expansion phase had reversed.

• Does a rising count of “new indication” supplements measure expanding clinical evidence, expanding marketing scope, or both?
• What does the original BMI threshold in the 2021 letter still exclude, and has FDA revised it in a later supplement?
• Would a company's own revenue disclosure, once opened, support or complicate an assumption of steadily growing demand?

The 2021 letter fixes one clear fact, an approval effective that day for a defined population; everything claimed about demand since rests on a separate kind of evidence this piece has not opened, and the gap is noted rather than filled with an estimate.

Source trail

1. NDA 215256 Approval Letter (Wegovy, semaglutide injection)www.accessdata.fda.gov · Source publication: 2021-06-07 · Retrieved 2026-09-16

   States the approved indication and BMI thresholds, and that approval is effective on the date of the letter.

2. Drugs@FDA overview for Application Number NDA215256www.accessdata.fda.gov · Source publication: not established · Retrieved 2026-09-16

   FDA's own record of the 4 June 2021 original approval date and subsequent efficacy and labeling supplements filed through 2026, as retrieved 16 September 2026.

Read across the evidence

• FDA authorised the first mRNA vaccine in December 2020
• Medicare telehealth visits jumped from under 1% to near half
• A cultured-chicken safety finding is not a market approval

Governance & change · All 100 historical records